Cuprina Closes $4.97M Public Offering at $1.15/Share; Underwriter Gets 172,900 Warrants
CUPR sits 16% above its 52-week low of $1.445 on light trading volume (0.1× avg).
Summary
Cuprina Holdings closed a $4.97 million public offering of 4.32 million shares at $1.15 each, with underwriter warrants and a 15% over-allotment option attached. The capital funds expansion and R&D for the micro-cap biomedical company.
Key Events · Financing and Capital Events · CUPR
-
Offering Closed at $1.15/Share
Cuprina closed its firm commitment offering of 4,322,489 Class A ordinary shares at $1.15 per share, raising approximately $4.97 million in gross proceeds before underwriting discounts and expenses.
-
Underwriter Warrants Issued
R. F. Lafferty received warrants to purchase 172,900 shares (4.0% of PO shares) at $1.265 per share, exercisable for 4.5 years beginning March 17, 2027, with registration rights and anti-dilution provisions.
-
Over-Allotment Option
The underwriter holds a 45-day option to purchase up to 648,373 additional shares (15% of PO shares) at the offering price, which would raise total gross proceeds to approximately $5.72 million.
-
Use of Proceeds
Net proceeds are earmarked for expansion into new businesses, R&D to expand product offerings, growth into new markets, brand awareness, equipment and infrastructure investment, and working capital.
Analysis · CUPR · Industrial Applications And Services
Cuprina Holdings closed its firm commitment public offering of 4,322,489 Class A ordinary shares at $1.15 per share, raising approximately $4.97 million in gross proceeds. The deal was priced at a deep discount to the company's prior trading levels, reflecting the capital urgency of a micro-cap biomedical firm. The underwriter, R. F. Lafferty, received warrants to purchase 172,900 shares at $1.265 (110% of the offering price), exercisable for 4.5 years starting March 17, 2027, plus a 45-day over-allotment option for up to 648,373 additional shares. Net proceeds will fund business expansion, R&D, new markets, and working capital. For a company with a market cap around $1.6 million, this raise is substantial and highly dilutive to existing holders, but it provides critical runway following the June FDA 510(k) clearance for MEDIFLY Maggots.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1668 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CUPR was trading at $1.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $1.45 to $14.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.